A strategic reorientation in the consortium structure

On 22 May 2025, the AI-Mind consortium, joined by the Project Officer and external experts, convened for a pivotal review meeting to assess project progress and plan the final steps ahead of its conclusion in February 2026. Discussions centred on actions to maximise the scientific, clinical and societal impact of AI-Mind in its final phase. This strategic reorientation began in early 2024 with a revision of the consortium’s structure, reflecting a shift in focus from foundational development to the implementation of the AI-Mind solution and ensuring its long-term sustainability. As part of this evolution, DET NORSKE VERITAS® (DNV) officially concluded its involvement on 31 December 2023, having successfully delivered its contributions. Simultaneously, three new partners: the University of Oslo (UiO), Pre Diagnostics AS and Roche joined the consortium on 1 January 2024, each bringing unique expertise to support AI-Mind’s next phase. DNV’s departure marked a key milestone in the consortium’s transition towards clinical application and industrial collaboration, reinforcing its commitment to real-world impact.

Strengthening trust through quality data assurance and governance

DNV joined AI-Mind in 2021 to address one of the central challenges in applying AI in clinical settings: building trust in data quality and governance. With a strong background in healthcare accreditation, medical device regulation (MDR) and digital assurance, DNV played a critical role in supporting AI-Mind’s mission to ensure robust, trustworthy systems for health data management.

In a project as interdisciplinary as AI-Mind, one of the greatest challenges is achieving mutual understanding among partners from different domains. Ensuring that we all share the same meaning for terms like ‘data quality’ or ‘pre-processing’ is no small feat. – noted Dr Harry Hallock, Senior Researcher at DNV.

During its nearly three-year involvement, DNV contributed to a range of key deliverables:

Data governance framework: In close collaboration with Oslo University Hospital (OUS), DNV assessed ethical and regulatory requirements for data sharing across Europe. The resulting Data Governance Plan (D1.3) and the AI-Mind Data Governance and Data Protection Framework (D1.4) provided essential foundations for secure, ethical data processing. Both are available on AI-Mind Share.
Technical infrastructure: DNV co-developed the central AI-Mind data warehouse in partnership with Lurtis, hosted on the University of Oslo’s Services for Sensitive Data (TSD) platform. In line with Open Science Cloud principles, the platform ensures secure, unified access to all AI-Mind data.
Data Quality Assurance: In collaboration with clinical partners, DNV helped define and implement rigorous data quality criteria that serve as a gateway before any data is uploaded to the central SSD platform, safeguarding homogeneity and usability across the project. Benefit from insights from the webinar on managing data in health projects.
Stakeholder Engagement: DNV supported AI-Mind’s broader objective to promote trust and regulatory alignment, drawing on its experience as a Notified Body under the MDR and as an applicant for the In Vitro Diagnostic Regulation (IVDR).

A necessary step towards impartiality

With the strategic entry of new partners, Pre Diagnostics AS and Roche, at the start of 2024, AI-Mind reinforced its path towards clinical validation and industrial uptake. Given DNV’s regulatory status and its obligation to remain independent from manufacturers of potentially certifiable technologies, its withdrawal from the consortium was a necessary step to preserve impartiality.

Towards industrial collaborations

The AI-Mind consortium expresses its sincere appreciation to DNV for its outstanding contributions. The frameworks, systems, and expertise developed through this partnership have laid a robust foundation for the project’s continued success. Now comprising 17 active partners spanning academia, healthcare, and industry, AI-Mind is well-positioned to accelerate the implementation of its cutting-edge dementia risk prediction tools. These tools offer new hope to individuals at risk of mild cognitive impairment (MCI) and dementia.

Stay tuned for the upcoming news, where we will introduce the new partners and share insights into their contributions to AI-Mind’s mission. For further updates, explore the AI-Mind website and follow us on our social media channels.